Boston Scientific to buy California anti-blood clot firm for up to $400M
Photo | Grant Welker
Boston Scientific headquarters in Marlborough
Marlborough-based medical device maker Boston Scientific announced on Tuesday it has entered an agreement to acquire California anti-blood clot technology maker Devoro Medical, Inc. of California for at least $320 million, with an additional $80 million upon achievement of certain clinical and regulatory milestones.
Those figures precede consideration of Boston Scientific’s 16% equity stake in the company, of which it is an investor.
Devoro is the developer of the WOLF Thrombectomy Platform, according to the announcement. The technology helps remove blood clots in the body's circulatory system, which can cause heart attacks, stroke, and other fatal health complications.
“Clot management remains a core focus of our business, and upon commercialization, this highly differentiated technology will complement and expand our offerings to a full suite of interventional strategies for thromboemboli, which also includes the EkoSonic Endovascular System and the AngioJet Thrombectomy System,” said Jeff Mirviss, executive vice president and president, Peripheral Interventions at Boston Scientific, in a statement.
WBJ Web Partners
Most Recent
Most Recent
0 Comments